US 12,129,310 B2
Materials and methods for enhanced linker targeting
Sanjaya Singh, Blue Bell, PA (US); Rajkumar Ganesan, Blue Bell, PA (US); Jun Chen, New Hope, PA (US); and Iqbal S. Grewal, Newton, PA (US)
Assigned to JANSSEN BIOTECH, INC., Horsham, PA (US)
Filed by Janssen Biotech, Inc., Horsham, PA (US)
Filed on Mar. 17, 2023, as Appl. No. 18/122,948.
Application 18/122,948 is a division of application No. 17/672,471, filed on Feb. 15, 2022, granted, now 11,639,396.
Claims priority of provisional application 63/149,872, filed on Feb. 16, 2021.
Claims priority of provisional application 63/149,892, filed on Feb. 16, 2021.
Claims priority of provisional application 63/149,883, filed on Feb. 16, 2021.
Claims priority of provisional application 63/149,865, filed on Feb. 16, 2021.
Claims priority of provisional application 63/149,857, filed on Feb. 16, 2021.
Prior Publication US 2023/0374156 A1, Nov. 23, 2023
Int. Cl. C07K 16/42 (2006.01); G01N 33/68 (2006.01)
CPC C07K 16/42 (2013.01) [G01N 33/6857 (2013.01); C07K 2317/14 (2013.01); C07K 2317/34 (2013.01)] 16 Claims
 
1. An isolated antibody, or antigen-binding fragment thereof, comprising
a heavy chain complementarity determining region 1 (CDR1), a heavy chain CDR2 and a heavy chain CDR3 of a heavy chain variable region (VH) comprising an amino acid sequence of SEQ ID NO: 29, and a light chain CDR1, a light chain CDR2 and a light chain CDR3 of a light chain variable region (VL) comprising an amino acid sequence of SEQ ID NO: 72.